The latest market intelligence, insights and interviews covering the cell and gene therapy industry's most pressing challenges, from translation to automation, manufacturing to market access, viral vectors to bioreactors.
Optimal mixing technology will greatly increase the productivity of cell expansion and directed differentiation of induced pluripotent stem cells, enabling the large-scale manufacturing of allogeneic cell therapy products derived from iPSCs.
Cell and gene therapies are set to revolutionise the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
